With recent approvals of pembrolizumab and nivolumab for the treatment of refractory deficient mismatch repair (dMMR) metastatic colorectal cancer (CRC), immunotherapy has made its way into the field of gastrointestinal oncology.
Data presented during the 2012 ASCO Annual Meeting demonstrated the potential of anti–PD-1 and anti–PD-L1 therapy for multiple cancers and introduced groundbreaking change in oncology research and treatment.
Both nivolumab alone and in combination with ipilimumab resulted in a promising disease control rate in patients with relapsing malignant pleural mesothelioma (MPM), according to the results of Abstract LBA8507.
The 3 mg/kg dose is considered the “standard” dose of ipilimumab, however, there has continued to be debate in the field about the most appropriate dose of ipilimumab, and clinical trials have continued to investigate the 10 mg/kg dose.
The 2011 ASCO Annual Meeting Plenary Session ushered in a renaissance for melanoma therapy with the promise of targeted therapy. Results of the BRIM-3 trial marked the beginning of the end of cytotoxic chemotherapy for melanoma.
The 2017 Clinical Immuno-Oncology Symposium achieved a successful first year, in which 950 physicians, researchers, translation-oriented scientists, and others gathered to learn about state-of-the-art developments in the science and application of immuno-oncology.